#USA #Portland #opioid use disorder #Buprenorphine #BRIXADI

Braeburn Presents Research at CPDD 2026

On June 12, 2026, Braeburn announced its intention to share valuable insights at the 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in Portland, Oregon from June 13 to June 17. The presentations will focus on real-world data related to its leading product, BRIXADI®, a buprenorphine extended-release injection, pertinent to the ongoing opioid crisis that has seen the rise of powerful synthetic opioids like fentanyl.

The Presentations

Braeburn will conduct two oral presentations and display two posters, each shedding light on various aspects of opioid use disorder (OUD) treatment:

1. First Dose Withdrawal Suppression with Buprenorphine

This first oral presentation aims to present findings from a post hoc analysis that addresses the efficacy of both Weekly and Monthly BRIXADI doses in moderating withdrawal symptoms among individuals with moderate to severe OUD. The research also investigates the correlation between plasma buprenorphine concentrations and the suppression of withdrawal symptoms and illicit drug use.

2. Treatment Retention Comparison

The second presentation will examine retention rates among patients who have recently used fentanyl and have received either BRIXADI or traditional sublingual buprenorphine. This retrospective analysis, based on electronic medical record data, provides important insights on how different delivery methods influence patient retention in a real-world setting over six months.

Posters on Trends and Patterns

In addition to oral presentations, Braeburn will display two posters:

1. Utilization Trends of Injectable Buprenorphine

The first poster will delve into retrospective data regarding dispensing trends of Weekly and Monthly BRIXADI, highlighting its utilization during a period marked by increasing synthetic opioid potency in the United States.

2. Cross-Sectional Analysis of Fentanyl-Associated Polysubstance Use

The second poster presents a national and regional snapshot of drug testing data from patients with substance use disorders who use fentanyl, revealing patterns of polysubstance use across the country from 2016 to 2025.

Importance of BRIXADI

BRIXADI is a critical treatment option for individuals experiencing moderate to severe opioid use disorder. It is designed for those who have already begun treatment with a transmucosal buprenorphine product or who are currently on buprenorphine therapy. It is important to emphasize that BRIXADI must be integrated into a holistic treatment strategy that encompasses counseling and psychosocial support.

Safety Information

Braeburn is committed to patient safety, and they have put in place a risk evaluation and mitigation strategy due to the hazards associated with intravenous administration of BRIXADI, which can lead to serious harm or even death. The company underscores the necessity of adhering to the guidelines for safe use to mitigate any risks related to its products.

Additionally, healthcare professionals and patients alike must be aware of the potential side effects and interactions, particularly when BRIXADI is combined with benzodiazepines or other CNS depressants.

Looking Ahead

As Braeburn prepares for the CPDD meeting, their focus is firmly set on providing impactful data that could help reshape the narrative in opioid use disorder treatment, especially during a time when synthetic opioids pose increasing threats to public health. By sharing their research, Braeburn aims to empower clinicians and improve care strategies for affected individuals, ultimately striving to counter the opioid epidemic through dedicated innovation and community partnership. For further details about BRIXADI and its indications, refer to BRIXADI.com.